The Latest Press Releases
Item 7.01 Regulation FD Disclosure.Attached as Exhibit 99.1 are materials to be used by representatives of Greif, Inc. (the “Company”) in connection with a presentation to be delivered at investor meetings this month, commencing on January 20, 2022. The materials will be accessible online through the Investors section of the Company’s website located at www.greif.com….
Read More “8-K Reg FD – GREIF, INC (0000043920) January 20” »
Item 2.02. Results of Operations and Financial Condition. On January 19, 2022, H.B. Fuller Company (the “Company”) announced its operating results for the fourth quarter and fiscal year ended November 27, 2021. A copy of the press release that discusses this matter is furnished as Exhibit 99.1 to, and incorporated by reference in, this report….
Read More “8-K Earnings – FULLER H B CO (0000039368) January 19” »
Item 8.01. Other Events. On January 20, 2022, R. R. Donnelley & Sons Company (the “Company”) issued a press release announcing that it is soliciting waivers and consents (the “Consent Solicitations”) from holders of its 6.500% Notes due 2023 (the “2023 Notes”), 6.000% Notes due 2024 (the “2024 Notes”), 6.125% Senior Secured Notes due 2026…
Read More “8-K Other Events – RR Donnelley & Sons Co (0000029669) January 20” »
Item 2.02.Results of Operations and Financial Condition. On January 20, 2022, M&T Bank Corporation announced its results of operations for the quarter ended December 31, 2021. The public announcement was made by means of a news release, the text of which is set forth in Exhibit 99.1 hereto. The information under Item 2.02 in this…
Read More “8-K Earnings – M&T BANK CORP (0000036270) January 20” »
Item 8.01 Other Events. On January 20, 2022, R. R. Donnelley & Sons Company (the “Company”) issued a press release announcing that the Company has received from a strategic party an update to the strategic party’s unsolicited non-binding “Alternative Acquisition Proposal” (as defined in the previously announced Agreement and Plan of Merger, dated as of…
Read More “8-K Other Events – RR Donnelley & Sons Co (0000029669) January 20” »
Item 7.01. Regulation FD Disclosure. On January 20, 2022, the Company issued a press release announcing the global launch of Terravis Energy green hydrogen energy systems. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference. The information under Item 7.01 of this Form 8-K and the exhibit attached…
Read More “8-K Reg FD – Worksport Ltd (0001096275) January 20” »
Item 5.07. Submission of Matters to a Vote of Security Holders. On January 19, 2022, Great Western Bancorp, Inc. (“GWB”) held a special meeting of stockholders (the “special meeting”) to consider certain proposals related to the Agreement and Plan of Merger (the “merger agreement”), dated as of September 15, 2021, by and between GWB and…
Read More “8-K Vote Other Events – Great Western Bancorp, Inc. (0001613665) January 19” »
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Effective January 19, 2022, the Board of Directors of Femasys Inc. (the “Company”) accepted William Witte’s resignation from the Board of Directors. Mr. Witte’s resignation did not result from any disagreement with the Company. In…
Read More “8-K Emp Changes Other Events – FEMASYS INC (0001339005) January 19” »
Item 7.01. Regulation FD Disclosure. On January 20, 2022, Conn’s, Inc. (the “Company”) issued a press release regarding the Company’s Investor Day beginning on January 20, 2022, at 9:00 a.m. Eastern time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company is furnishing as…
Read More “8-K Reg FD – CONNS INC (0001223389) January 20” »
Item 8.01. Other Events. On January 20, 2022, Sorrento Therapeutics, Inc. (the “Company”) issued a press release announcing the release of new data on the Omicron variant neutralizing antibody (nAb) STI-9167, COVISHIELD, an advanced stage antibody discovered and developed for clinical trials in an ongoing collaboration between immunologists and virologists at the Company and the…
Read More “8-K Other Events – Sorrento Therapeutics, Inc. (0000850261) January 20” »